PUNE, India, June 23, 2017 /PRNewswire/ --
RnRMarketResearch.com added Prostate Specific Antigen (Gamma
Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or
KLK3 or EC 3.4.21.77) Pipeline Review H1 2017 research reports that
provides comprehensive information on the Prostate Specific
Antigentargeted therapeutics, complete with analysis by
indications, stage of development and molecule type.
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3
or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline
Review, H1 2017 reviews key players involved, targeted therapeutics
development with respective active and dormant or discontinued
projects. Prostate Specific Antigen Pipeline is a
glycoprotein enzyme encoded by the KLK3 gene. PSA is secreted by
the epithelial cells of the prostate gland. It is hydrolyzes
semenogelin-1 this leads to the liquefaction of the seminal
coagulum.
Companies discussed in this report include: Advaxis Inc,
Aeterna Zentaris Inc, Bavarian Nordic A/S, Inovio Pharmaceuticals
Inc, Inspyr Therapeutics Inc, OncBioMune Pharmaceuticals Inc.
Drugs profile discussed in this report include: ADXS-PSA,
AEZS-120, Cellular Immunotherapy to Target PSA for Prostate Cancer,
Cellular Immunotherapy to Target PSA, PAP, Survivin and hTERT for
Metastatic Hormone Refractory Prostate Cancer, G-114, G-115,
INO-5150, Monoclonal Antibody 1 to Inhibit PSA for Prostate Cancer,
Monoclonl Antibody to Inhibit PSA for Prostate Cancer,
Prostatac.
Order a Purchase copy of this report @
http://www.rnrmarketresearch.com/contacts/purchase?rname=1082616
.
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3
or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) pipeline
Target constitutes close to 12 molecules. Out of which
approximately 9 molecules are developed by companies and remaining
by the universities/institutes. The molecules developed by
companies in Phase III, Phase II, Phase I, IND/CTA Filed and
Preclinical stages are 1, 1, 2, 1 and 4 respectively. Similarly,
the universities portfolio in Phase II stages comprises 3
molecules, respectively. Report covers products from therapy areas
Oncology which include indications Prostate Cancer, Metastatic
Hormone Refractory (Castration Resistant and Androgen-Independent)
Prostate Cancer. The report enhances decision making capabilities
and help to create effective counter strategies to gain competitive
advantage. It strengthens R&D pipelines by identifying new
targets and MOAs to produce first-in-class and best-in-class
products.
Featured News & Press Releases cover by this report
include: Jun 07, 2017: OncBioMune
Protects ProscaVax Cancer Treatment Technology in Hong Kong. Jun 01,
2017: Protocol Submitted to FDA for Phase 2 Clinical Trial
of ProscaVax as Immunotherapy for Early-Stage Prostate Cancer.
May 03, 2017: OncBioMune Completes
Enrollment in Phase 1 Trial of ProscaVax for Prostate Cancer.
Apr 19, 2017: Bavarian Nordic
Announces Initiation of Phase 2. Combination Trial of PROSTVAC,
Ipilimumab and Nivolumab in Patients with Localized Prostate
Cancer. Feb 02, 2017: OncBioMune
Announces Presentation on ProscaVax at the 2017 American
Association for Cancer Research Meeting. Jan
26, 2017: Latest Clinical Data from OncBioMune Supports
Safety and Therapeutic Profile of ProscaVax for Prostate Cancer for
Upcoming Phase 2 Clinical Trials. Jan 18,
2017: Departments of Urology and Oncology Approve Protocol
for OncBioMune's Phase 2/3 Trial of ProscaVax for Prostate Cancer
in Mexico. Jan 10, 2017: OncBioMune Submitting Clinical
Trial of World's First Early-Stage Prostate Cancer Vaccine to The
Cancer Therapy Evaluation Program (CTEP) at the National Cancer
Institute. Jan 04, 2017: Bavarian
Nordic Provides Update on Anticipated Timing of PROSPECT Study.
Explore more reports of Biotechnology at
http://www.rnrmarketresearch.com/reports/life-sciences/biotechnology
.
Other Related Reports:
Prostate cancer- Market Insights, Epidemiology and Market
Forecast-2023
Prostate cancer Market Insights, Epidemiology and Forecast-2023
Reports provides an overview of the disease and global market
trends of the Indication for the seven major markets ie:
United States, EU5 (France, Germany, Italy, Spain,
UK) and Japan. The Report covers
the therapeutics market revenue; average cost of therapy, treatment
practice and Prostate cancer forecasted market share for ten years
to 2023 segmented by seven major markets. In addition, the report
also includes global forecast of epidemiology of Prostate cancer
till 2023.
About Us:
RnRMarketResearch.com is an online database of market research
reports offer in-depth analysis of over 5000 market segments. The
library has syndicated reports by leading market research
publishers across the globe and also offer customized market
research reports for multiple industries.
Contact Us:
Ritesh Tiwari
2nd Floor, Metropole,
Bund Garden Road,
Pune - 411001,
India.
Tel: +1-888-391-5441
E-mail: sales@rnrmarketresearch.com